Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 320 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hepatitis B Clear all
Not listed Phase 2 Interventional

4-Methylumbelliferone as a Treatment for Chronic HBV/HCV

NCT00225537
View directory record Official record
Conditions
Chronic Hepatitis C, Chronic Hepatitis B
Interventions
4-Methylumbelliferone (Heparvit®)
Drug
Lead sponsor
MTmedical Institute of Health
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2006 · Synced Oct 20, 2026, 11:13 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

PREHEVBRIO Pregnancy Outcomes Registry

NCT06097312
View directory record Official record
Conditions
Vaccine Exposure During Pregnancy
Interventions
Data collection
Other
Lead sponsor
VBI Vaccines Inc.
Industry
Eligibility
Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2032
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 20, 2026, 11:13 PM EDT
Terminated Phase 3 Interventional Results available

Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B

NCT01369199
View directory record Official record
Conditions
Hepatitis B
Interventions
Entecavir and peginterferon
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Honolulu, Hawaii + 11 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 20, 2026, 11:13 PM EDT
Completed No phase listed Observational

Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection

NCT01350648
View directory record Official record
Conditions
Hepatitis B, Hepatitis C, HIV-HCV Co-Infection
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
569 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 20, 2026, 11:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

UCLA-Amity Parolee Health Promotion Study

NCT01844414
View directory record Official record
Conditions
Hepatitis B, Hepatitis C, HIV, Drug Addiction
Interventions
Parolee Comprehensive Care + Phone Coach, Parolee Brief HBV Program + Phone Coach, Usual Care Group
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 20, 2026, 11:13 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rapid HIV, Hep C, and Syphilis Screening in a Rural Street Medicine Clinic

NCT07317687
View directory record Official record
Conditions
HIV Testing, HEPATITIS C (HCV), Syphilis, Hepatitis B Virus (HBV)
Interventions
Rapid Fingerstick Test, Blood Draw for lab test
Diagnostic Test
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Harpers Ferry, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 20, 2026, 11:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thousand Asian American Study

NCT02596438
View directory record Official record
Conditions
Hepatitis B
Interventions
Hepatitis B
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
1,076 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 20, 2026, 11:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Response to Booster Doses of Hepatitis B Vaccine in Children and Adolescents

NCT00141999
View directory record Official record
Conditions
Hepatitis
Interventions
hepatitis B vaccine
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
5 Years to 14 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2008
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Oct 20, 2026, 11:13 PM EDT
Completed Phase 1 Interventional

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B

NCT01590641
View directory record Official record
Conditions
Hepatitis B, HBV
Interventions
Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Costa Mesa, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 20, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection

NCT01368497
View directory record Official record
Conditions
Hepatitis B
Interventions
Entecavir and peginterferon
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 20, 2026, 11:13 PM EDT
Terminated Phase 2 Interventional

GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype

NCT01384383
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
GS-5885, GS-9451, RBV, PEG
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
26
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 20, 2026, 11:13 PM EDT
Completed No phase listed Observational

Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection

NCT00004850
View directory record Official record
Conditions
Hepatitis C, Hepatitis B
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 11:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection

NCT00423891
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
Entecavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
2 Years to 18 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
9
States / cities
San Francisco, California • Hartford, Connecticut • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 20, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B

NCT04193189
View directory record Official record
Conditions
HIV Infection, Hepatitis B
Interventions
HEPLISAV-B, ENGERIX-B
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 20, 2026, 11:13 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Blood Collection Biorepository for Liver Disease Research

NCT03025074
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis(NASH), Hepatitis C, Hepatitis B, Fibrosis, Cirrhosis, Fatty Liver, Obesity, Childhood, Bariatric Surgery Candidate
Interventions
Not listed
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
7 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2099
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 20, 2026, 11:13 PM EDT
Completed No phase listed Observational

Social-environmental, Psychosocial, Behavioral, Clinical and Biological Drivers of Disparities in Liver Disease Progression Among Korean American With Chronic Hepatitis B Infection

NCT05117541
View directory record Official record
Conditions
Chronic Viral Hepatitis, Hepatitis B Infection
Interventions
Interview, Biospecimen Collection, Electronic Health Record Review
Other · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
365 participants
Timeline
2021 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 20, 2026, 11:13 PM EDT
Active, not recruiting No phase listed Observational

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

NCT05064553
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Interventions
Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test
Device · Diagnostic Test
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
76
States / cities
Chandler, Arizona • Sun City, Arizona • Bakersfield, California + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 20, 2026, 11:13 PM EDT
Completed Phase 1 Interventional

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

NCT02143401
View directory record Official record
Conditions
Cirrhosis, Hepatitis B Infection, Hepatitis C Infection, Metastatic Malignant Solid Neoplasm, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Refractory Malignant Neoplasm, Stage IV Hepatocellular Carcinoma AJCC v7, Unresectable Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Navitoclax, Pharmacological Study, Sorafenib, Sorafenib Tosylate
Other · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
10
States / cities
Scottsdale, Arizona • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 20, 2026, 11:13 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

NCT06497504
View directory record Official record
Conditions
Hepatitis B
Interventions
Bepirovirsen, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Bakersfield, California • San Francisco, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 20, 2026, 11:13 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of a Hepatitis B Vaccine in Immunosuppressed Patients

NCT04199715
View directory record Official record
Conditions
Hepatitis B
Interventions
Heplisav-B
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 20, 2026, 11:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

VaxTeen Hepatitis B Vaccine Booster Study

NCT00144313
View directory record Official record
Conditions
Hepatitis
Interventions
hepatitis B vaccine
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
13 Years to 16 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Sep 21, 2007 · Synced Oct 20, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Acceptability of a Vaginal Microbicide

NCT00111943
View directory record Official record
Conditions
HIV Infections, Hepatitis B, Chronic
Interventions
1% tenofovir gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2007
U.S. locations
2
States / cities
Birmingham, Alabama • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 20, 2026, 11:13 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)

NCT00412750
View directory record Official record
Conditions
Hepatitis B
Interventions
Telbivudine (LdT), peginterferon alpha-2a
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Oct 20, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants

NCT06058390
View directory record Official record
Conditions
Hepatitis B
Interventions
Bepirovirsen
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 20, 2026, 11:13 PM EDT